# Contents

**Preface**  
*page xvii*

**Acknowledgments**  
*xxi*

## 1 The biomedical device and drug industry and their markets  
*page 1*

**Learning points**  
1

1.1 The healthcare industry components and large cycle trends  
1

1.2 Biomedical technology – definition and scope, applications  
3

1.3 Drugs and biotechnology – definition and scope  
4

1.4 Devices and diagnostics – definition and scope  
8

1.4.1 Medical devices industry  
8

1.4.2 Diagnostics – IVD industry  
9

1.4.3 Healthcare IT and digital therapeutics  
11

1.5 Industrial value chains and industry analysis  
13

1.5.1 Industry analysis databases  
13

1.5.2 What is an industrial value chain?  
13

1.5.3 Drug development process  
15

1.5.4 Medical device and diagnostic development process  
17

1.6 Competitive analysis of an industry or sector with Porter’s Five Forces model  
18

1.6.1 Competitiveness summary for the pharmaceutical industry  
20

1.6.2 Competitiveness summary for the biomedical device industry  
22

1.6.3 Competitiveness summary for the diagnostics market  
25

1.7 Technology trends in biomedical device and drug development  
26

1.7.1 Drug development technology trends  
27

1.7.2 Medical device and diagnostics technology trends  
30

1.7.3 Emerging technologies and materials in the nucleic acid diagnostics field  
31

1.7.4 Robotics, 3D printing, connected devices, virtual and augmented reality, mobile technologies, artificial intelligence, and others  
32

1.8 Convergence of technologies in biotechnology  
33

1.9 Summary  
36

Exercises  
37
# Contents

References and additional readings 38
Appendix 1.1 Industry classification system for government and other databases 39

## 2 Markets of interest and market research steps

### Learning points

2.1 Opportunity recognition 44
   - 2.1.1 How do scientists and businesspeople assess the value in a technology? 47
   - 2.1.2 Value of technological innovation 48

2.2 Methods of market research 48
   - 2.2.1 Reports, projections, and historical data 49
   - 2.2.2 Experimental 50
   - 2.2.3 Observational 50
   - 2.2.4 Surveys to collect information 52
   - 2.2.5 Potential sources for secondary market information 53

2.3 Human health-related markets: scope and size 53
   - 2.3.1 Market size segmented by application 55
   - 2.3.2 Market size segmented by geography for drugs, devices, and IVD 55
   - 2.3.3 How big is the market for my technology/innovation? 55

2.4 Market drivers and hurdles 58
   - 2.4.1 Drivers 58
   - 2.4.2 Hurdles 59

2.5 The referral chain: developing market context and understanding customer needs 60
   - 2.5.1 Market context: insight into biology or disease pathology 61
   - 2.5.2 Market context: the referral chain 63
   - 2.5.3 What competitive or alternate products exist? 66
   - 2.5.4 Defining the end user 66
   - 2.5.5 Defining the indication 69

2.6 Market research in the context of medical device design and development 70

2.7 Summary 70

Exercises 74

References and additional readings 75

## 3 Starting up your company

### Learning points

3.1 Building the team 78
   - 3.1.1 How do you start attracting and building a team in a startup company? 78
   - 3.1.2 Who should be on the team? 79
Table of Contents

3.1.3 Hiring a CEO 79
3.1.4 Why do we need a board of directors? when? and who should be on it? 81
3.1.5 Advisory board members 82
3.1.6 Roles in the startup company 83
3.2 What’s in a business plan? 84
  3.2.1 Key contents of a business plan 85
  3.2.2 The commercialization plan 86
  3.2.3 The financial plan 87
  3.2.4 Identify the assumptions 87
  3.2.5 Investor perspective summary 87
3.3 What is a business model? 88
  3.3.1 Business models for drug, device, and cell and gene therapy innovators 92
  3.3.2 Dominant business models among life sciences and biotechnology/biopharma companies 93
3.4 Some practical tips on presenting the business plan 96
3.5 Starting a company 97
  3.5.1 Distributing equity 97
  3.5.2 Doing science for product development vs academic science 101
  3.5.3 Setting up a lab 101
  3.5.4 Setting company culture: 104
  3.5.5 Role of the CEO 104
  3.5.6 Milestone-based planning 105
  3.5.7 Customer and product development feedback 105
3.6 Financing a company 106
  3.6.1 Sourcing of financing to early milestones 107
  3.6.2 Valuations 108
  3.6.3 Preparing for due diligence 112
  3.6.4 Selecting your investors 113
3.7 Nondilutive funding sources 113
3.8 Operations in a growing company 114
  3.8.1 Meetings 114
  3.8.2 Conflict resolution among staff and management team 115
3.9 Summary 118

Exercises 118
References and additional readings 119

4 Intellectual property and licensing 122

Learning points 122
4.1 Types of intellectual property 122
4.2 Patents 123
  4.2.1 Patent rights 124
  4.2.2 Types of patents 124
4.2.3 What cannot be patented (from the United States Patent and Trademark Office [USPTO] website) 125
4.2.4 What type of invention or discovery is patentable? 128

4.3 Protecting intellectual property by filing a patent 130
4.3.1 How long do issued patents last in the United States? 130
4.3.2 How much does it cost to get a patent? 130
4.3.3 Considerations before filing a patent 130
4.3.4 Is the idea or invention ready to patent? 132
4.3.5 Determine the inventor(s) 133
4.3.6 Steps to prepare a patent filing 134
4.3.7 What is in a patent? How to read an issued patent 134
4.3.8 Provisional patent application process in United States 137
4.3.9 Priority date, grace period, and public disclosure 137
4.3.10 International patent filings and the Patent Cooperation Treaty (PCT) process 139
4.3.11 Patent prosecution process 140
4.3.12 Patent infringement 142
4.3.13 “Freedom to practice” or “freedom to operate” 143
4.3.14 Types of applications 145

4.4 Trademarks 145
4.4.1 Why register your trademark? 146
4.4.2 Filing a trademark with the USPTO 146
4.4.3 International filing of trademarks 146

4.5 Copyrights 146
4.6 Trade secrets 147

4.7 IP commercialization and technology transfer 148
4.7.1 Commercial use of intellectual property 148
4.7.2 Technology transfer in academic research institutions 149
4.7.3 The Bayh–Dole Act 149

4.8 Licensing 151
4.8.1 Key nonfinancial terms of license agreements 151
4.8.2 Financial terms in a license 155
4.8.3 “Boilerplate” clauses in the license agreement 158
4.8.4 Pros and cons of various types of licenses 158

4.9 Biotech business models and IP licensing strategies 159
4.10 Summary 160

Exercises 160
References and additional readings 161

5 New product development (NPD) 163

Learning points 163
5.1 Why have a new product development (NPD) process—just get it done! 164
5.2 Planning and preparing an NPD process for biomedical technologies (drugs, devices, and diagnostics) 165
5.2.1 The project proposal document 166
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.2.2 Strategy and competency of the company and goal of the project</td>
<td>166</td>
</tr>
<tr>
<td>5.2.3 Product life cycle planning</td>
<td>166</td>
</tr>
<tr>
<td>5.2.4 Market research inputs</td>
<td>167</td>
</tr>
<tr>
<td>5.2.5 Identify key unknowns and risks</td>
<td>168</td>
</tr>
<tr>
<td>5.2.6 Build a milestone-based plan for product development</td>
<td>168</td>
</tr>
<tr>
<td>5.2.7 Specific risks known to occur frequently during the development</td>
<td>170</td>
</tr>
<tr>
<td>5.3 Killing the project early or try some more?</td>
<td>173</td>
</tr>
<tr>
<td>5.3.1 Early failure is better than late failure in biomedical product</td>
<td>173</td>
</tr>
<tr>
<td>5.3.2 When to kill a project?</td>
<td>174</td>
</tr>
<tr>
<td>5.4 Uncertainty-based view of product development processes</td>
<td>176</td>
</tr>
<tr>
<td>5.5 Stage-gate approach</td>
<td>178</td>
</tr>
<tr>
<td>5.5.1 Stages and gates</td>
<td>178</td>
</tr>
<tr>
<td>5.5.2 How to configure a stage-gate process plan for my biomedical</td>
<td>179</td>
</tr>
<tr>
<td>product</td>
<td></td>
</tr>
<tr>
<td>5.5.3 Unique features of biomedical development</td>
<td>180</td>
</tr>
<tr>
<td>5.6 Ethical requirements in biomedical product development</td>
<td>180</td>
</tr>
<tr>
<td>5.6.1 IACUC – Institutional Animal Care and Use Committee</td>
<td>180</td>
</tr>
<tr>
<td>5.6.2 IRB – institutional review board</td>
<td>181</td>
</tr>
<tr>
<td>5.7 Define the product and process = indications, endpoints, and target</td>
<td>183</td>
</tr>
<tr>
<td>product profile</td>
<td></td>
</tr>
<tr>
<td>5.8 Typical drug development process</td>
<td>190</td>
</tr>
<tr>
<td>5.8.1 Discovery and preclinical testing</td>
<td>191</td>
</tr>
<tr>
<td>5.8.2 Distinctions in preclinical development of biotechnology drugs</td>
<td>195</td>
</tr>
<tr>
<td>(large molecule biologicals)</td>
<td></td>
</tr>
<tr>
<td>5.8.3 Drug candidate clinical testing to market approval</td>
<td>196</td>
</tr>
<tr>
<td>5.8.4 Manufacturing, marketing, sales, and reimbursement</td>
<td>202</td>
</tr>
<tr>
<td>5.8.5 Keeping a record for the FDA</td>
<td>202</td>
</tr>
<tr>
<td>5.8.6 General stage-gate process for new drug development:</td>
<td>202</td>
</tr>
<tr>
<td>5.9 Typical diagnostics development process</td>
<td>202</td>
</tr>
<tr>
<td>5.10 Typical device development process</td>
<td>209</td>
</tr>
<tr>
<td>5.10.1 Discovery, feasibility, and optimization – design and</td>
<td>210</td>
</tr>
<tr>
<td>preclinical testing</td>
<td></td>
</tr>
<tr>
<td>5.10.2 Special considerations for device clinical trial design</td>
<td>215</td>
</tr>
<tr>
<td>5.10.3 Device manufacturing</td>
<td>219</td>
</tr>
<tr>
<td>5.10.4 Keeping records for the FDA</td>
<td>219</td>
</tr>
<tr>
<td>5.10.5 Device development stage-gate process</td>
<td>219</td>
</tr>
<tr>
<td>5.11 A few general notes on biomedical product development</td>
<td>219</td>
</tr>
<tr>
<td>5.12 Project management</td>
<td>222</td>
</tr>
<tr>
<td>5.12.1 Project management tools – Gantt charts and critical path</td>
<td>222</td>
</tr>
<tr>
<td>5.12.2 Team composition</td>
<td>223</td>
</tr>
<tr>
<td>5.12.3 Team management in a matrix environment</td>
<td>224</td>
</tr>
</tbody>
</table>
## Contents

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.13</td>
<td>Formulating budgets</td>
<td>225</td>
</tr>
<tr>
<td>5.14</td>
<td>How to get your project funded in a larger organization</td>
<td>227</td>
</tr>
<tr>
<td>5.14.1</td>
<td>The art of persuasion</td>
<td>229</td>
</tr>
<tr>
<td>5.14.2</td>
<td>Business case</td>
<td>229</td>
</tr>
<tr>
<td>5.14.3</td>
<td>Valuation decision – net present value (NPV)</td>
<td>230</td>
</tr>
<tr>
<td>5.14.4</td>
<td>Stakeholders</td>
<td>230</td>
</tr>
<tr>
<td>5.15</td>
<td>Outsourcing product development</td>
<td>231</td>
</tr>
<tr>
<td>5.16</td>
<td>Summary of preclinical certifications and laboratory regulations</td>
<td>233</td>
</tr>
<tr>
<td>5.17</td>
<td>Summary</td>
<td>235</td>
</tr>
<tr>
<td></td>
<td>Exercises</td>
<td>236</td>
</tr>
<tr>
<td></td>
<td>References and additional readings</td>
<td>236</td>
</tr>
</tbody>
</table>

## 6 The regulated market: gateway through the FDA

### Learning points

6.1 FDA role and significance for biomedical product development 239
   - 6.1.1 Introduction and history 239
   - 6.1.2 Role of the FDA and significance for product development 241

6.2 Organization and scope of the FDA 241
   - 6.2.1 Divisions of the FDA 241
   - 6.2.2 What the FDA does not regulate 242
   - 6.2.3 What does the FDA regulate? 243
   - 6.2.4 Friends not foe 243
   - 6.2.5 Science rules – most of the time! 244
   - 6.2.6 International harmonization 244

6.3 Regulatory pathways for drugs (biologicals or synthetic chemicals) 246
   - 6.3.1 Classify your product 246
   - 6.3.2 Definition of drug product 249
   - 6.3.3 Preclinical studies regulated by the FDA 251
   - 6.3.4 Filing an investigational new drug application (IND; or form FDA 1571) 252
   - 6.3.5 Working with the FDA in formally arranged meetings 254
   - 6.3.6 New drug application (NDA) submission 254
   - 6.3.7 Clinical trials done in foreign countries 256
   - 6.3.8 Drug master files 256
   - 6.3.9 Abbreviated pathway for duplicate drugs (generic or biosimilar drugs) – the ANDA 257
   - 6.3.10 An abbreviated approval pathway for reformulated versions of drugs 505(b)(2) 258
   - 6.3.11 Regulatory pathway for over-the-counter drugs 258
   - 6.3.12 Post-market clinical studies (Phase IV) and safety surveillance by the FDA 258
   - 6.3.13 Schematics of IND, NDA, and ANDA review processes 259
   - 6.3.14 Speeding up access to drugs 259
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.3.15</td>
<td>Market exclusivity for new drugs and the Hatch–Waxman Act 1984</td>
<td>264</td>
</tr>
<tr>
<td>6.3.16</td>
<td>Drugs: helpful FDA websites and the Electronic Orange Book</td>
<td>265</td>
</tr>
<tr>
<td>6.4</td>
<td>Orphan drugs</td>
<td>266</td>
</tr>
<tr>
<td>6.5</td>
<td>Devices: Regulatory pathways and development considerations</td>
<td>266</td>
</tr>
<tr>
<td>6.5.1</td>
<td>Step 1: determine the jurisdiction of the FDA center – is it a device?</td>
<td>267</td>
</tr>
<tr>
<td>6.5.2</td>
<td>Step 2: classify the medical device – what controls and regulations apply?</td>
<td>268</td>
</tr>
<tr>
<td>6.5.3</td>
<td>Step 3: determine the specific path and marketing application required to be submitted</td>
<td>269</td>
</tr>
<tr>
<td>6.5.4</td>
<td>Device regulatory pathways in the European Union (EU)</td>
<td>271</td>
</tr>
<tr>
<td>6.5.5</td>
<td>Working with the FDA in formal meetings</td>
<td>271</td>
</tr>
<tr>
<td>6.5.6</td>
<td>General controls and exempt devices (FDA and EMA)</td>
<td>272</td>
</tr>
<tr>
<td>6.5.7</td>
<td>Preclinical considerations – special controls and QSR for Class II and III devices</td>
<td>273</td>
</tr>
<tr>
<td>6.5.8</td>
<td>The use of master files</td>
<td>275</td>
</tr>
<tr>
<td>6.5.9</td>
<td>510(k) submission type and content and CE technical documentation</td>
<td>276</td>
</tr>
<tr>
<td>6.5.10</td>
<td>PMA submission content</td>
<td>278</td>
</tr>
<tr>
<td>6.5.11</td>
<td>Types of PMA submissions</td>
<td>279</td>
</tr>
<tr>
<td>6.5.12</td>
<td>Humanitarian use devices (HUDs)</td>
<td>279</td>
</tr>
<tr>
<td>6.5.13</td>
<td>Devices: helpful FDA websites</td>
<td>279</td>
</tr>
<tr>
<td>6.6</td>
<td>Diagnostics: regulatory pathways and NPD considerations</td>
<td>281</td>
</tr>
<tr>
<td>6.6.1</td>
<td>IVD – regulatory clearance or approval steps to market</td>
<td>283</td>
</tr>
<tr>
<td>6.6.2</td>
<td>Preclinical and clinical considerations for IVDs</td>
<td>284</td>
</tr>
<tr>
<td>6.6.3</td>
<td>CLIA program</td>
<td>285</td>
</tr>
<tr>
<td>6.6.4</td>
<td>Analyte-specific reagents or “home-brew” tests</td>
<td>286</td>
</tr>
<tr>
<td>6.7</td>
<td>Regulatory guidelines for co-development of pharmacogenetic diagnostic tests and drugs</td>
<td>288</td>
</tr>
<tr>
<td>6.8</td>
<td>Combination products, artificial intelligence and software, genetic material, and tissues</td>
<td>291</td>
</tr>
<tr>
<td>6.8.1</td>
<td>Combination products – drugs and devices bundled together</td>
<td>291</td>
</tr>
<tr>
<td>6.8.2</td>
<td>Software and artificial intelligence in medical products</td>
<td>292</td>
</tr>
<tr>
<td>6.8.3</td>
<td>Cellular, tissue, and gene therapies</td>
<td>297</td>
</tr>
<tr>
<td>6.9</td>
<td>Summary</td>
<td>306</td>
</tr>
<tr>
<td></td>
<td>Exercises</td>
<td>306</td>
</tr>
<tr>
<td></td>
<td>References and additional readings</td>
<td>306</td>
</tr>
<tr>
<td>7</td>
<td>Manufacturing</td>
<td>309</td>
</tr>
<tr>
<td></td>
<td>Learning points</td>
<td>309</td>
</tr>
<tr>
<td>7.1</td>
<td>Technology transfer to manufacturing operations (drugs, devices, and diagnostics)</td>
<td>309</td>
</tr>
</tbody>
</table>
## Chapter 7: Regulatory compliance in manufacturing

### 7.2 Regulatory compliance in manufacturing
- **7.2.1 Current good manufacturing practices**
- **7.2.2 Validation**
- **7.2.3 Drug manufacture regulations – control systems reviewed for compliance**
- **7.2.4 Device and diagnostic manufacture regulations – control systems reviewed for compliance**

### 7.3 Manufacturing standards
- **7.3.1 What are standards and what is their purpose?**
- **7.3.2 Who sets standards?**
- **7.3.3 Which of the thousands of standards apply to my product?**
- **7.3.4 What are “clean room” standards?**
- **7.3.5 ISO 13585 standard for medical device manufacturers**

### 7.4 Manufacturing in drug development
- **7.4.1 Process validation before approval**
- **7.4.2 Bulk drug scale-up and production stages**
- **7.4.3 Commercial manufacturing planning**

### 7.5 Manufacturing in devices and diagnostics
- **7.5.1 Design for manufacturability**
- **7.5.2 Design for assembly**

### 7.6 Manufacturing in diagnostics
- **7.6.1 Labeling requirements for IVDs**

### 7.7 Buy or build

### 7.8 Summary

### Exercises

## Chapter 8: Reimbursement, marketing, sales, and product liability

### 8 Reimbursement, marketing, sales, and product liability
- **8.1 Healthcare system in the United States**
  - **8.1.1 Economic impact of the healthcare system**
  - **8.1.2 Insurance coverage of the U.S. population**
  - **8.1.3 Who pays for the national healthcare expenditures?**
- **8.2 Flow of payments and distribution models for products and services**
- **8.3 Distribution and payment flow for biomedical product types**
  - **8.3.1 Drugs/biologics product payment and distribution model**
  - **8.3.2 Devices and diagnostics product payment and distribution model**
- **8.4 Components of the reimbursement process**
  - **8.4.1 Coverage**
  - **8.4.2 Coding**
  - **8.4.3 Payment**
## Contents

8.5 Reimbursement planning activities 393
8.6 Reimbursement path for self-administered drugs (mostly pills) 395
8.7 Reimbursement path for devices and infused drugs 395
  8.7.1 Reimbursement path for physician-administered drugs 397
  8.7.2 Reimbursement path for devices 398
8.8 Major differences among selected national healthcare and reimbursement systems 409
8.9 Marketing 410
8.10 Sales 414
8.11 Product liability 415
8.12 Summary 417
Exercises 417
References and additional readings 417

Glossary 420
Index 429